Payment overview · 2025
General Payments
$4,460.31
56 reported records · 16 companies
Healthcare provider profile · identity verified
Raymond Chan, MD
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1477741981
Verified facts
What the public records show
CMS Open Payments records show Raymond Chan, MD received $4,460.31 in general payments during 2025 across 56 reported records.
Amgen Inc. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $740.68 | 16.6% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $679.92 | 15.2% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $581.84 | 13.0% | 8 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $420.24 | 9.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $380.46 | 8.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $375.00 | 8.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $272.73 | 6.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $202.13 | 4.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $166.47 | 3.7% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $147.73 | 3.3% | 2 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $147.33 | 3.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $125.00 | 2.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $124.76 | 2.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $47.60 | 1.1% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $27.27 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.15 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,460.31 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $420.24 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $375.00 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $311.20 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $307.26 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $272.73 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $229.92 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $202.13 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $166.47 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $147.73 | 2 | 2025 |
Source payment records
|
|||||
| HYDRUS Microstent Normalized: hydrus microstent |
Device | Alcon Vision LLC | $147.33 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $130.46 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $124.76 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $122.22 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $81.84 | 4 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 133 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 34 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 22 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
93 | 25 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 36 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
22 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 1055 | 265 |
| Atorvastatin Calcium | Atorvastatin Calcium | 893 | 242 |
| Amlodipine Besylate | Amlodipine Besylate | 731 | 220 |
| Vascepa | Icosapent Ethyl | 654 | 140 |
| Tamsulosin Hcl | Tamsulosin Hcl | 434 | 118 |
| Metformin Hcl | Metformin Hcl | 424 | 95 |
| Simvastatin | Simvastatin | 340 | 80 |
| Omeprazole | Omeprazole | 332 | 137 |
| Alendronate Sodium | Alendronate Sodium | 281 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 80 |
| Diclofenac Sodium | Diclofenac Sodium | 223 | 132 |
| Pravastatin Sodium | Pravastatin Sodium | 205 | 60 |
| Diclofenac Epolamine | Diclofenac Epolamine | 202 | 77 |
| Metformin Hcl Er | Metformin Hcl | 179 | 52 |
| Allopurinol | Allopurinol | 160 | 41 |
| Januvia | Sitagliptin Phosphate | 154 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 151 | 89 |
| Ammonium Lactate | Ammonium Lactate | 150 | 89 |
| Mometasone Furoate | Mometasone Furoate | 145 | 93 |
| Fenofibrate | Fenofibrate,micronized | 140 | 41 |
| Finasteride | Finasteride | 137 | 39 |
| Jardiance | Empagliflozin | 133 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 126 | 33 |
| Trazodone Hcl | Trazodone Hcl | 118 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 29 |
| Glipizide Er | Glipizide | 94 | 21 |
| Farxiga | Dapagliflozin Propanediol | 93 | 25 |
| Mupirocin | Mupirocin | 91 | 70 |
| Atenolol | Atenolol | 90 | 26 |
| Montelukast Sodium | Montelukast Sodium | 88 | 30 |
| Meclizine Hcl | Meclizine Hcl | 85 | 67 |
| Lisinopril | Lisinopril | 80 | 23 |
| Raloxifene Hcl | Raloxifene Hcl | 76 | 14 |
| Azelastine Hcl | Azelastine Hcl | 73 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 26 |
| Acarbose | Acarbose | 70 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 18 |
| Meloxicam | Meloxicam | 67 | 57 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 66 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 26 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 59 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 57 | 28 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 55 | 21 |
| Procto-Med Hc | Hydrocortisone | 53 | 23 |
| Synthroid | Levothyroxine Sodium | 51 | 14 |
| Glimepiride | Glimepiride | 48 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 13 |
| Azithromycin | Azithromycin | 45 | 43 |
| Famotidine | Famotidine | 45 | 15 |
| Ketoconazole | Ketoconazole | 45 | 25 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 44 | suppressed |
| Carvedilol | Carvedilol | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 42 | 31 |
| Rybelsus | Semaglutide | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 22 |
| Colchicine | Colchicine | 37 | 17 |
| Celecoxib | Celecoxib | 36 | 30 |
| Loperamide | Loperamide Hcl | 35 | 34 |
| Donepezil Hcl | Donepezil Hcl | 34 | 11 |
| Kerendia | Finerenone | 34 | 12 |
| Naproxen | Naproxen | 33 | 32 |
| Hydrocortisone | Hydrocortisone | 31 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 28 | suppressed |
| Gabapentin | Gabapentin | 27 | 13 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 16 |
| Eliquis | Apixaban | 21 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | 11 |
| Vemlidy | Tenofovir Alafenamide | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Entecavir | Entecavir | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 13 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,460.31 · 56 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAMZYOS, COMIRNATY, CREON, Cologuard Collection Kit, EVENITY, Fluad, Flucelvax, HYDRUS Microstent, IBSRELA, JARDIANCE, Kerendia, LINZESS, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, REZDIFFRA, SHINGRIX, TRELEGY ELLIPTA, VYALEV, Wegovy, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error